Actively Recruiting
Effect of C-peptide on Hypoglycemic Counterregulation
Led by University of Cincinnati · Updated on 2026-02-17
38
Participants Needed
1
Research Sites
187 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Iatrogenic hypoglycemia is the most prominent barrier to the safe, effective management of blood sugar in people with type 1 diabetes due to periodic over-insulinization. During insulin-induced hypoglycemia, glucagon secretion is diminished in type 1 diabetes which, in turn, reduces hepatic glucose production and increases the depth and duration of hypoglycemic episodes. We have observed that the naturally occurring protein C-peptide increases glucagon secretion in dogs during insulin-induced hypoglycemia, which increases hepatic glucose production; the experiments in this application will shed light on the translation of this finding to the human.
CONDITIONS
Official Title
Effect of C-peptide on Hypoglycemic Counterregulation
Who Can Participate
Eligibility Criteria
You may qualify if you...
- BMI less than 30 kg/m2
You will not qualify if you...
- Pregnant or lactating women
- Cigarette smoking
- Presence of HIV or hepatitis
- Presence of cardiovascular disease
- Presence of microvascular disease
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Cincinnati
Cincinnati, Ohio, United States, 45267-0547
Actively Recruiting
Research Team
J
Jason Winnick, PhD
CONTACT
N
Natalie Whitsett
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
CROSSOVER
Primary Purpose
BASIC_SCIENCE
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here